In February 2022, Robert M. Califf was confirmed as the FDA Commissioner for the second time. A seasoned physician and leader who is late in his career, one can expect that his term will be impactful and influential. Advancements in medicine have required a faster approval process from the FDA while at the same time taxing payers financially and demanding robust evidence from manufacturers.
Virtual-First Health Plans: Will These Plans Accelerate the Use of Telemedicine and Prevent its Decline While Lowering the Cost of Care?
Dive into Virtual-First Health Plans with Jennifer Williams as she explains how these entrants seek to leverage the virtual space to improve patient outcomes and enhance the patient experience, while simultaneously lowering the cost of care.
What are the implications of China becoming a hot spot for oncology drug development for the US? Explore this competitive landscape with Jennifer Williams as she reveals the potential for a price war and the possible effects.
Explore the top reasons payers are adopting clinical pathways and guidelines in the oncology space. Jennifer Williams shares the tumor types being targeted, as well as future possibilities payers are exploring in non-oncology specialties to further leverage pathways and guidelines.